Search results

Skip to results

Area of interest

Area of interest

Type

Type

Status

Status

Last updated

Last updated

Guidance programme

Advice programme

Showing 46 to 60 of 131 results for hepatitis

  1. How many people in the UK are infected with chronic hepatitis B and C and which subgroups of the population do they come from?

    Question How many people in the UK are infected with chronic hepatitis B and C and which subgroups of the population do they come from?...

    Research recommendation
    Published
    9 June 2015

  2. What impact does increased knowledge and awareness of hepatitis B and C among the general public have on the uptake of testing and treatment?

    Question What impact does increased knowledge and awareness of hepatitis B and C among the general public have on the uptake of testing...

    Research recommendation
    Published
    9 June 2015

  3. Sexual Health in Practice Training to increase HIV testing in primary care

    advice and health promotion advice regarding risk reduction (e.g. condoms, hepatitis vaccination) following this individual rapid risk...

    Shared learning
    Last updated
    28 November 2018

  4. The OraQuick HCV point‑of‑care test for rapid detection of hepatitis C virus antibodies (MIB24)

    NICE has developed a medtech innovation briefing (MIB) on the OraQuick HCV point-of-care test for rapid detection of hepatitis C virus antibodies

    Medtech innovation briefing
    Published
    2 March 2015

  5. Obeticholic acid for treating primary biliary cholangitis (TA443)

    Evidence-based recommendations on obeticholic acid (Ocaliva) for treating primary biliary cholangitis in adults.

    Technology appraisal guidance
    Published
    26 April 2017
    View recommendations

    Sections for TA443

  6. What cost-effective interventions can be used to increase hepatitis B case-finding among migrant populations in primary and secondary care?

    Question What cost-effective interventions can be used to increase hepatitis B case-finding among migrant populations in primary and...

    Research recommendation
    Published
    9 June 2015

  7. Gastroparesis in adults: oral erythromycin (ESUOM13)

    Summary of the evidence on oral erythromycin for gastroparesis (delayed stomach emptying) in adults to inform local NHS planning and decision-making

    Evidence summary
    Published
    18 June 2013

  8. Etanercept, infliximab and adalimumab for the treatment of psoriatic arthritis (TA199)

    Evidence-based recommendations on etanercept (Enbrel), infliximab (Remicade) and adalimumab (Humira) for treating active and progressive psoriatic arthritis in adults.

    Technology appraisal guidance
    Published
    25 August 2010
    View recommendations

    Sections for TA199

  9. How cost effective are alternative testing sites, such as community pharmacist programmes, for increasing the number of people who are tested and treated for hepatitis B and C?

    for hepatitis B and C? Any explanatory notes(if applicable) None. Source guidance details Comes from guidance Hepatitis B...

    Research recommendation
    Published
    9 June 2015

  10. Which interventions for other communicable diseases could be used to encourage people at increased risk of hepatitis B and C infection to take up the offer of testing and treatment?

    communicable diseases could be used to encourage people at increased risk of hepatitis B and C infection to take up the offer of testing...

    Research recommendation
    Published
    9 June 2015

  11. ALT values for children and young people:- Further research should be undertaken to examine whether the upper limit of normal ALT values for adults (below 30 IU/ml for males and below 19 IU/ml for females) are appropriate for use in children and young people with chronic hepatitis B when making decisions on when to initiate treatment.

    females) are appropriate for use in children and young people with chronic hepatitis B when making decisions on when to initiate...

    Research recommendation
    Published
    9 June 2015

  12. Durvalumab with gemcitabine and cisplatin for treating unresectable or advanced biliary tract cancer (TA944)

    Evidence-based recommendations on durvalumab (Imfinzi) with gemcitabine and cisplatin for treating locally advanced, unresectable, or metastatic biliary tract cancer in adults.

    Technology appraisal guidance
    Published
    10 January 2024
    View recommendations

    Sections for TA944

  13. HIV testing: encouraging uptake (QS157)

    This quality standard covers interventions to improve the uptake of HIV testing among people who may have undiagnosed HIV. It focuses on increasing testing to reduce undiagnosed infection in people at increased risk of exposure. It describes high-quality care in priority areas for improvement.

    Quality standard
    Published
    7 September 2017
    View quality statements

    Sections for QS157

  14. Leg ulcer infection: antimicrobial prescribing (NG152)

    This guideline sets out an antimicrobial prescribing strategy for adults with leg ulcer infection. It aims to optimise antibiotic use and reduce antibiotic resistance.

    Antimicrobial prescribing guideline
    Published
    11 February 2020
    View recommendations

    Sections for NG152

  15. LIVERFASt for assessing and monitoring liver fibrosis, activity and steatosis (MIB317)

    NICE has developed a medtech innovation briefing (MIB) on LIVERFASt for assessing and monitoring liver fibrosis, activity and steatosis .

    Medtech innovation briefing
    Published
    21 February 2023